Market Cap (In USD)
494.02 Million
Revenue (In USD)
4.62 Million
Net Income (In USD)
-147.74 Million
Avg. Volume
78.28 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 7.11-17.02
- PE
- -
- EPS
- -
- Beta Value
- 1.423
- ISIN
- US00370M1036
- CUSIP
- -
- CIK
- 1956827
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Marc M. P. de Garidel M.B.A.
- Employee Count
- -
- Website
- https://www.abivax.com
- Ipo Date
- 2023-10-20
- Details
- ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
More Stocks
-
VRSVeriSign, Inc.
VRS
-
001530Di Dong Il Corporation
001530
-
KOOL
-
FRFXF
-
KAMRF
-
LONKFLonking Holdings Limited
LONKF
-
CONFIPETConfidence Petroleum India Limited
CONFIPET
-
LFT